Open AccessAntiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Author(s) -
Shaker A. Mousa,
Jeffrey M. Bozarth,
Mark S. Forsythe,
Sharon M. Jackson,
Andrew W. Leamy,
Margretta Diemer,
Ram P. Kapil,
Robert M. Knabb,
Michael C. Mayo,
S K Pierce
Publication year - 1994
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.89.1.3
Subject(s) - medicine , antithrombotic , platelet , pharmacology , ex vivo , ticlopidine , platelet aggregation inhibitor , aspirin , platelet membrane glycoprotein , in vivo , abciximab , platelet activation , antiplatelet drug , bleeding time , clopidogrel , in vitro , chemistry , biochemistry , platelet aggregation , biology , microbiology and biotechnology , myocardial infarction , conventional pci
Currently used antiplatelet drugs, including aspirin, ticlopidine, and others, are effective against certain but not all of the many endogenous platelet activators. Because of their limited efficacy, a significant number of serious thromboembolic complications still occur, highlighting the need for a more effective therapy. Thus, we have identified a systemically active peptide analogue (DMP 728) of the arginine-glycine-aspartic acid (RGD) recognition sequence that mediates the binding of ligands such as fibrinogen to the platelet glycoprotein (GP) IIb/IIIa receptors. The goals of the present study were to determine the antiplatelet and antithrombotic efficacies of DMP 728 in various arterial thrombosis models.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom